Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in moderate to severe chronic plaque-type psoriasis with or without psoriatic arthritis
TCTR20161028001Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in plaque psoriasis, psoriatic arthritis (PsA), sponsored by Novartis. Planned start Feb 2017; status: not yet recruiting.
02
Drugs
secukinumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on TCTR20161028001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20161028001.